Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML

摘要: The pathophysiology of IDH mutations in tumorigenesis is increasingly described, yet the prognostic significance IDH1 and IDH2 AML remains controversial. primary objective this study was to define natural history prognosis patients with or provide historical survival expectations. A total 826 treated from 2010 2014 at a single institution were evaluated, including 167 (20%) mutations. Median age 62 years (range 18-92). There 59 IDH1-R132, 83 IDH2-R140, 23 IDH2-R172 Clinicopathologic characteristics associated IDH-mutations included older age, less frequent therapy-related status, increased incidence intermediate-risk cytogenetics, FLT3-ITD mutations, NPM1 Remission rates (CR/CRi) by treatment status were: induction, 68%; Salvage-1 (S1), 42%; Salvage-2 beyond (S2+), 27%. No difference response identified mutation status. Similarly, overall (OS) not dependent on within any cohort. median OS 15.4 months 8.7 S1, 4.8 S2+. This analysis defines clinical outcome both front-line salvage settings, confirms that rate for IDH-mutated wild-type comparable. provides contemporary data be used comparison results novel investigational (e.g., selective inhibitor) strategies.